Site icon Money & Markets, LLC

Buy Medifast (MED) Stock to Expand Your Profits … Not Your Waistline

Medifast stock MED

In this episode of The Bull & The Bear podcast, I tell you why Medifast stock (NYSE: MED) is worth a spot in your 2021 portfolio.

Two of the most common New Year’s resolutions are also the hardest to obtain: 

  • Losing weight or being healthier. 
  • Making or saving more money. 

Losing weight is difficult because temptations are everywhere. 

Making more money in financial markets is difficult because you never know what could knock the market back next. 

But I’ve found a company that offers the best of both worlds — proven products to help with weight loss that will push its stock higher and pad your profits. 

Well, I did just that using Chief Investment Strategist Adam O’Dell’s six-factor Green Zone Ratings system. 

I’ll tell you about it in this episode of The Bull & The Bear. 

But first, I’ll tell you why this company is positioned to outperform the broader market by three times in the next 12 months. 

The Weight Loss Market Rebound 

According to Research & Markets — a global research firm — the U.S. weight loss market topped $79 billion in 2019. 

The COVID-19 pandemic trimmed that market by 9% to around $71 billion. People cut their finances to deal with mass layoffs, furloughs and working from home. 

But some market segments have actually grown … specifically the meal replacement segment (think shakes and nutrition bars). 

That segment was expected to grow 5.4% in 2020 (final figures aren’t yet available), to $5.25 billion.  

Shakes and nutrition bars are easily available at your local grocery store, and they are relatively inexpensive compared to joining a gym or having an expensive surgery. 

The company I found offers these shakes and nutrition bars as well as other weight loss management products. 

Medifast Stock Boosts Your Profits by Helping People Lose Weight 

Medifast Inc.’s (NYSE: MED) share price rose more than 365% in the last nine months. 

In this episode of The Bull & The Bear, I tell you why Medifast stock is worth a spot in your portfolio for 2021. 

Adam and Charles Sizemore focused on the health and lifestyle sector with their last two picks for their Green Zone Fortunes serviceDecember’s pick is already up more than 50%, while January’s has risen more than 20% in a short amount of time.  

If you want to access our hand-picked monthly stocks, along with research and guidance on the best time to buy or sell, check out Adam’s Millionaire Master Class here. 

Remember, knowing the data and the details about a specific stock or sector of the market helps you determine whether it is worth investing in. 

That’s why we do the work for you and give you our analysis every week. 

The Bull & The Bear 

Led by Adam O’Dell and a team of finance journalists, traders and experts, Money & Markets gives you the information you need to protect your nest egg, grow your wealth and safeguard your financial well-being. 

You can listen to The Bull & The Bear on Apple Podcasts, SpotifyAmazon and Google Podcasts. Make sure to subscribe and leave us a review. 

Be sure to also subscribe to our YouTube channel for more videos like my weekly Marijuana Market Update. 

Have something you want us to talk about? Email thebullandthebear@moneyandmarkets.com and give us your thoughts. 

Check out moneyandmarkets.comand sign up for our free newsletters that deliver you the most important and unbiased financial news, commentary, and actionable advice. 

Also, follow us on: 

Facebook
Twitter
LinkedIn 

Safe trading, 

Matt Clark 

Research Analyst, Money & Markets 

Matt Clark is the research analyst for Money & Markets. He’s the host of our podcast, The Bull & The Bear, as well as the Marijuana Market Update. Before joining the team, he spent 25 years as an investigative journalist and editor — covering everything from politics to business. 

Exit mobile version